Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-283275
Filing Date
2025-11-14
Accepted
2025-11-14 17:05:47
Documents
74
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q eldn-20250930.htm   iXBRL 10-Q 3312223
2 EX-31.1 eldn-ex31_1.htm EX-31.1 16732
3 EX-31.2 eldn-ex31_2.htm EX-31.2 17008
4 EX-32.1 eldn-ex32_1.htm EX-32.1 11266
5 EX-32.2 eldn-ex32_2.htm EX-32.2 11331
  Complete submission text file 0001193125-25-283275.txt   12648794

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eldn-20250930.xsd EX-101.SCH 1356489
77 EXTRACTED XBRL INSTANCE DOCUMENT eldn-20250930_htm.xml XML 2687670
Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36620 | Film No.: 251488034
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)